Relmada Therapeutics, Inc. RLMD Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s other accrued liabilities?
- Relmada Therapeutics, Inc. (RLMD) reported other accrued liabilities of $76.1K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s other accrued liabilities changed year-over-year?
- Relmada Therapeutics, Inc.'s other accrued liabilities increased by 12.6% year-over-year, from $67.6K to $76.1K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s other accrued liabilities?
- Over 3 years (2020 to 2025), Relmada Therapeutics, Inc.'s other accrued liabilities has grown at a 2.1% compound annual growth rate (CAGR), from $126.2K to $134.4K.